Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol IIIC inhibitors
LUMC highlighted Acurx's new class of promising antimicrobials, ibezapolstat and related analogues Novel chemotype specifically targeting gram-positive bacteria through an unexploited target Ibezapolstat ready to enter pivotal Phase 3 clinical trials for C. difficile Infection (CDI), with no cross resistance reported to date
Ibezapolstat has previously been granted FDA QIDP and Fast-Track Designations and has received SME (Small and Medium-sized Enterprise) designation by the EMA
STATEN ISLAND, N.Y., June 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ('Acurx' or the 'Company') is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international pivotal Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI).
The Company today announced that a presentation of a poster and an oral presentation regarding Acurx's overall DNA pol IIIC inhibitor platform was presented at a scientific conference on May 21 by Mia Urem, PhD, from Leiden University Medical Center in the Netherlands entitled: 'A Unique Inhibitor Conformation Selectively Targets the DNA Polymerase PolC of Gram-Positive Priority Pathogens'. This scientific conference is sponsored by the Federation of American Societies for Experimental Biology and is the premier venue for the newest research and technological trends in molecular 'machines' inside the human body that ensure DNA replication and expression of genes to create proteins that make up a cell. The distinctive non-planar conformation of ACX-801 and IBZ, together with high conservation of the induced binding pocket in PolC, suggests that this is a general mechanism for this class of inhibitor and is conserved in Gram-positive bacteria.
According to Dr. Wiep Klaas Smits, Associate Professor/Principal Investigator, Leiden University Medical Center: 'Our findings with regards to the structural biology of DNA pol IIIC in complex with inhibitors have important implications for the development of this novel class of antibiotics to treat high priority, multi-drug resistant, gram-positive infections.'
Acurx's Executive Chairman, Bob DeLuccia, stated: 'This research outcome provides a deeper understanding of the mechanism of action and selectivity of ibezapolstat in the gut. These data will guide the rational design of new compounds with improved inhibitory activity and drug-like characteristics that will be crucial in addressing the pandemic of antimicrobial resistance.'
POSTER AND PRESENTATION ARE ON ACURX WEBSITE www.acurxpharma.com
About the Federation of American Societies for Experimental Biology
Since its inception 20 years ago, this conference has been the premier venue for the newest research and technological trends that aid in studying the molecular 'machines' inside the human body. These biological elements ensure faithful DNA replication and expression of genes to create the many proteins that make up a cell. The Machines on Genes scientific conference covers all aspects that govern the central building blocks of life, DNA replication, transcription, and translation, as well as activities that impact these processes such as DNA repair, DNA editing, and RNA editing. There is special emphasis on how they work, how they interact with one another, and how they may be used as diagnostic tools or as targets for novel therapies.
About Leiden University Medical Center
Antimicrobial resistant microorganisms are a major threat to global health and pose a significant economic burden. Increasing resistance to multiple agents and resistance to so called last-resort antibiotics underscore the necessity to develop therapeutics that have a novel mode of action. DNA replication is a process that can be successfully targeted by small molecules. Ibezapolstat, an inhibitor of the replicative DNA polymerase pol IIIC from Gram-positive bacteria identified by screening library of dGTP analogues, has shown promising results for the treatment of Clostridioides difficile Infection in a recent Phase 2a clinical trial, but the molecular basis of selective inhibition is not fully characterized as no structural information is available on pol IIIC proteins from pathogens. Ongoing research project will determine the structure of pol IIIC from the multidrug-resistant organisms methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci (VRE) and/or penicillin resistant Streptococcus pneumoniae (PRSP) in the absence and presence of lead compounds. These results will reveal the structural space of inhibitor-binding and guide the rational design of inhibitors with optimal pharmacological properties and organism-specificity that will be demonstrated by in vitro polymerase inhibition assays and in vivo minimal inhibitory concentration determination.
Leiden University was the first university to be established in the Netherlands. Its motto is praesidium libertatis – bastion of freedom. The University wishes to create an increasingly attractive and challenging working climate for top academics and young researchers that is guided by quality and excellence. Leiden University Medical Center (LUMC) research aims to meet the highest international standards of quality and academic integrity. LUMC promotes excellent research through greater collaboration, both disciplinary and interdisciplinary; stronger positioning and greater scope for top talent; and better supervision and more support for young researchers.
The presented research was performed in part as a public-private partnership that includes the Dutch Top Sector Life Sciences and Health ('Topconsortium voor Kennis en Innovatie' or 'TKI' Life Sciences and Health) and is represented by Stichting Life Sciences Health – TKI (aka, Health~Holland). This foundation is tasked by the Dutch government to promote and stimulate public-private partnerships (PPPs) to undertake R&D projects in the life sciences. To promote such partnerships, the Minister of Economic Affairs and Climate Policy has allocated certain funds to Stichting LSH-TKI, to grant allowances to projects under the TKI-programme Life Sciences & Health. Stichting LSH-TKI has designated the Board of Directors of LUMC as delegated grantor for the PPP allowance allocated to the LUMC.
Together with Acurx Pharmaceuticals the PPP has led to the research project entitled 'Bad bugs, new drugs: elucidation of the structure of DNA polymerase C of multidrug resistant bacteria in complex with novel classes of antimicrobials.' The collaboration project was co-funded by the PPS Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships.
Acurx previously announced that it had received positive regulatory guidance from the EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program.
The primary efficacy analysis will be performed using a Modified Intent-To-Treat (mITT) population. This will result in an estimated 450 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard- of-care vancomycin, enrolled into the initial Phase 3 trial. The trial design not only allows determination of ibezapolstat's ability to achieve Clinical Cure of CDI as measured 2 days after 10 days of oral treatment, but also includes assessment of ibezapolstat's potential effect on reduction of CDI recurrence in the target population. In the event non-inferiority of ibezapolstat to vancomycin is demonstrated, further analysis will be conducted to test for superiority.
About the Ibezapolstat Phase 2 Clinical Trial
The completed multicenter, open-label single-arm segment (Phase 2a) study was followed by a double-blind, randomized, active-controlled, non-inferiority, segment (Phase 2b) at 28 US clinical trial sites which together comprise the Phase 2 clinical trial. This Phase 2 clinical trial was designed to evaluate the clinical efficacy of ibezapolstat in the treatment of CDI including pharmacokinetics and microbiome changes from baseline. from study centers in the United States. In the Phase 2a trial segment,10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days. All patients were followed for recurrence for 28± 2 days. Per protocol, after 10 patients of the projected 20 Phase 2a patients completed treatment (100% cured infection at End of Treatment (10 of 10).
In the Phase 2b trial segment, 32 patients with CDI were enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours, in each case, for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI. The two treatments were identical in appearance, dosing times, and number of capsules administered to maintain the blind.
In the Phase 2b trial, the Clinical Cure rate in patients with CDI was 96% (25 out of 26 patients), based on 10 out of 10 patients (100%) in Phase 2a in the Modified Intent to Treat Population, plus 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population, who experienced Clinical Cure during treatment with ibezapolstat.
Notably, in the combined Phase 2 trial, 100% (25 of 25) ibezapolstat-treated patients ) who had Clinical Cure at EOT) (End of Treatment) remained cured through one month after EOT, as compared to 86% (12 of 14) for the vancomycin patient group. Ibezapolstat was well-tolerated, with no serious adverse events assessed by the blinded investigator to be drug- related. The Company is confident that based on the pooled Phase 2 ibezapolstat Clinical Cure rate of 96%, Sustained Clinical Cure Rate of 100% and the historical vancomycin Clinical Cure Rate range of 70% to 92% and a Sustained Clinical Cure historical range of 42% to 74%, we will demonstrate non-inferiority of ibezapolstat to vancomycin in Phase 3 trials, in accordance with the applicable FDA Guidance for Industry (October 2022), with favorable differentiation in both Clinical Cure and Sustained Clinical Cure.
In the Phase 2 clinical trial (both trial segments), the Company also evaluated pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance, especially overgrowth of healthy gut microbiota Actinobacteria and Firmicute phylum species during and after therapy. Phase 2a data demonstrated complete eradication of colonic C. difficile by day three of treatment with ibezapolstat as well as the observed overgrowth of healthy gut microbiota, Actinobacteria and Firmicute phyla species, during and after therapy. Very importantly, emerging data show an increased concentration of secondary bile acids during and following ibezapolstat therapy which is known to correlate with colonization resistance against C. difficile. A decrease in primary bile acids and the favorable increase in the ratio of secondary-to-primary bile acids suggest that ibezapolstat may reduce the likelihood of CDI recurrence when compared to vancomycin. The company also reported positive extended clinical cure (ECC) data for ibezapolstat (IBZ), its lead antibiotic candidate, from the Company's recently completed Phase 2b clinical trial in patients with CDI. This exploratory endpoint showed that 5 of 5 IBZ patients followed for up to three months following Clinical Cure experienced no recurrence of infection. Furthermore, ibezapolstat-treated patients showed lower concentrations of fecal primary bile acids, and higher beneficial ratio of secondary to primary bile acids than vancomycin-treated patients.
About Ibezapolstat
Ibezapolstat is the Company's lead antibiotic candidate planning to advance to international Phase 3 clinical trials to treat patients with C. difficile infection. Ibezapolstat is a novel, orally administered antibiotic, being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome.
In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In 2019, FDA granted 'Fast Track' designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI.
About Clostridioides difficile Infection
According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, 2015, NEJM). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, NEJM. Based on internal estimates, the recurrence rate for the antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and a mortality rate of approximately 9.3%.
About the Microbiome in C. difficile Infection and Bile Acid Metabolism
C. difficile can be a normal component of the healthy gut microbiome, but when the microbiome is thrown out of balance, the C. difficile can thrive and cause an infection. After colonization with C. difficile, the organism produces and releases the main virulence factors, the two large clostridial toxins A (TcdA) and B (TcdB). (Kachrimanidou, Microorganisms 2020.) TcdA and TcdB are exotoxins that bind to human intestinal epithelial cells and are responsible for inflammation, fluid and mucous secretion, as well as damage to the intestinal mucosa. Bile acids perform many functional roles in the GI tract, with one of the most important being maintenance of a healthy microbiome by inhibiting C. difficile growth. Primary bile acids, which are secreted by the liver into the intestines, promote germination of C. difficile spores and thereby increase the risk of recurrent CDI after successful treatment of an initial episode. On the other hand, secondary bile acids, which are produced by normal gut microbiota through metabolism of primary bile acids, do not induce C. difficile sporulation and therefore protect against recurrent disease. Since ibezapolstat treatment leads to minimal disruption of the gut microbiome, bacterial production of secondary bile acids continues which may contribute to an anti-recurrence effect. Beneficial effects of bile acids include a decrease in primary bile acids and an increase in secondary bile acids in patients with CDI, which was observed in the Company's Ph2a trial results and previously reported (Garey, CID, 2022). In the Ph2b trial, ibezapolstat-treated patients showed lower concentrations of fecal primary bile acids, and higher beneficial ratio of secondary to primary bile acids than vancomycin-treated patients.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials next year. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words 'believes,' 'anticipates,' 'plans,' 'expects,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.;
David P. Luci, President & CEO
Tel: 917-533-1469;
Email: [email protected]
View original content: https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-announces-presentation-of-results-from-leiden-university-medical-center-public-private-partnership-for-its-dna-pol-iiic-inhibitors-at-the-federation-of-american-societies-for-experimental-biology-scientific-c-302475161.html
SOURCE Acurx Pharmaceuticals, Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Washington Post

28 minutes ago

• Washington Post

Putin boasts about Russia's economy despite recession fears

ST. PETERSBURG, Russia — President Vladimir Putin on Friday hailed Russia's economic outlook, saying it has managed to curb inflation and ease its reliance on energy exports. His optimistic account in a speech at the St. Petersburg International Economic Forum contrasted with somber statements by some members of his government who warned at the same conference that Russia could face a recession. Economic Minister Maxim Reshetnikov had said Thursday that the country is 'on the brink of going into a recession.'

New York Times

29 minutes ago

• New York Times

NBA star Kevin Durant invests in PSG, to consult on ‘potential' basketball expansion plans

Two-time NBA champion Kevin Durant has expanded his relationship with Qatar Sports Investments (QSI), investing directly into UEFA Champions League winners Paris Saint-Germain as part of a strategic partnership that will also see Durant consult on the club's 'potential plans' to expand into basketball. Advertisement In March, QSI revealed it had been approached about the possibility of launching a basketball franchise in Paris and that it had expressed an interest. The approach related to the NBA's potential expansion into Europe, under the moniker NBA Europe, and plans that have been developed under the leadership of commissioner Adam Silver. The Athletic reported in March that Silver would pitch the NBA Board of Governors with the outline of a plan to launch a new pro basketball league in Europe within the next couple of years. The prospective league had been hoping to attract 16 teams, which would include franchises in markets such as London and Paris, as well as possible defectors from the EuroLeague. Since then, there have been indications from NBA and EuroLeague executives that there may be a way to collaborate. EuroLeague CEO Paulius Motiejunas conceded to The Athletic that 'it is becoming more obvious that we have to work together', while NBA deputy commissioner Mark Tatum said the NBA intends to be the 'operator' of 'the top tier league in Europe.' Sources familiar with the planning, who wished to remain anonymous to protect relationships, confirmed PSG's ambitions in basketball relate to NBA Europe and indicated that it would be for the NBA and EuroLeague to thrash out what happens in Paris, where there is already a Paris team playing in EuroLeague. QSI, along with other major sports investors, are waiting for the NBA to launch its process for franchises in Europe. It remains to be seen whether NBA Europe will be a competitor or if some form of partnership with EuroLeague may develop. Durant's direct investment in PSG is a slightly convoluted affair. The 36-year-old had previously invested a single-digit million shareholding in the team, according to sources briefed on the matter but not authorized to speak publicly. This was made via his investment firm Boardroom, but this injection came via a financial vehicle created by the private equity firm Arctos Sports Partners. Arctos itself had purchased a 12.5 percent stake in the French team in December 2023, a deal which at the time valued PSG at around €4.25billion ($4.58bn; £3.64bn, currency figures based on the rates when the deal was announced). This latest deal, however, sees Durant exit the stake acquired via Arctos, with his exit taken up via other money from the fund, which means Arctos has not diluted and its stake remains at around 12.5 percent. Advertisement Durant has now taken a direct minority stake in PSG through Boardroom in tandem with his business partner and former long-time agent Rich Kleiman. The size of his investment is roughly the same as previously, but PSG is not disclosing the precise sum. In these partnerships, the access to the famous athlete and their connections, clout and expertise is, in any case, more valuable to the Qatari fund, which is not short of money. Durant, whose fourth Olympic gold medal came last year in Paris, said in a release: 'It is an honour to partner with QSI and be a shareholder in Paris Saint-Germain — a club and a city that is so close to my heart. This club has big plans ahead and I can't wait to be a part of the next phase of growth; and to explore new investment opportunities with QSI.' The stake, however, is just one aspect of the deal as PSG and Boardroom have also signed a strategic investment partnership. This means Boardroom and QSI will team up on commercial, investment and media content initiatives, as well as advising on PSG's growth in the U.S., while the parties will also develop merchandise together. Most crucially, perhaps, Durant will consult 'on Paris Saint-Germain's multi-sport strategy, including potential plans in basketball,' the release said, opening the door to Durant leading the way on NBA Europe's launch plans. Nasser Al-Khelaifi, chairman of Qatar Sports Investments, added: 'QSI is pleased to welcome Kevin Durant as a direct shareholder in Paris Saint-Germain and strategic partner of our group. We continually seek to elevate the club and our broader portfolio through high-impact partnerships that bring strategic value, innovation, and global perspective. Together with Kevin, we look forward to developing ambitious initiatives that will drive the continued global growth of Paris Saint-Germain and QSI.' Advertisement PSG's multi-sport empire already includes men's and women's soccer, youth soccer, handball and judo. Basketball will add to the set. PSG recently announced it is looking at fresh sites to build a new stadium away from their current home at Parc des Princes. The team is studying sites in Massy and Poissy and is examining a modern construct that will feature state-of-the-art sports and entertainment options. The club wants its stadium to be part of a multi-functional area and a destination. The team's CEO, Victoriano Melero, told Reuters last week that PSG may take inspiration from SoFi Stadium in Inglewood, Ca., which is a $5billion home to the NFL's Los Angeles Rams and Los Angeles Chargers, while it has hosted headline concerts for superstars such as Taylor Swift. It will also host eight matches during the World Cup in 2026 and events in the Olympic Games in 2028, but PSG have noted how the area has become a sports, entertainment and residential hub in Hollywood Park. The LA Clippers play at the Intuit Dome, a newly opened NBA arena a mile from the stadium. Analysis by senior NBA writer Joe Vardon Paris has always been a coveted market and center to any designs Silver has of starting a new league in Europe. This is no secret, nor is it a secret that the NBA's intended partner there is PSG because of the enormous financial and marketing power of the soccer conglomerate. PSG and its Qatari owners don't need Durant's money, nor, really, even his media company. But they are likely going to build a new arena — Durant could consult. As the league comes online, they'll need a practice facility and coaches, where perhaps Durant could weigh in. Imagine if Durant… played for PSG basketball. At age 36, Durant, who wants to continue playing, can sign a two-year extension this summer (presumably after he's traded by the Phoenix Suns). Silver has suggested it could take a few years to bring NBA Europe online. What if the league launched with Durant as its signature player? Don't rule it out — I have had prominent NBA coaches tell me they'd love to live and coach in Paris once their contracts run out. Advertisement Otherwise, Durant as a name partner with PSG could, conceivably, help in a likely competition for fans with the current Parisian pro team, Paris Basketball, which competes in the EuroLeague and top French pro league, has a new arena, and also holds near exclusivity for games at Paris' largest arena, Bercy.

CNN

31 minutes ago

• CNN

Britain's lawmakers vote to legalize assisted dying, a landmark move after a fraught national debate

Lawmakers in Britain have narrowly approved a bill to legalize assisted dying for terminally ill people, capping a fraught debate in Parliament and across the country that cut across political, religious and legal divides. MPs passed the bill by 314 votes to 291, in their final say on the question. The bill – which has split lawmakers and sparked impassioned conversations with their constituents the breadth of Britain – will now move to the House of Lords for its final rounds of scrutiny. Friday's vote puts Britain firmly on track to join a small club of nations that have legalized the process, and one of the largest by population to allow it. It allows people with a terminal condition and less than six months to live to take a substance to end their lives, as long as they are capable of making the decision themselves. Two doctors and a panel would need to sign off on the choice. Canada, New Zealand, Spain and most of Australia allow assisted dying in some form, as do several US states, including Oregon, Washington and California. Friday's vote in Parliament coincided with a charged public debate about whether the state should be dictating the choices available to Britons in the final moments of their lives. Proponents included Esther Rantzen, a BBC TV presenter with advanced lung cancer, who argued that the choice would save millions from unnecessary suffering. 'If we don't vote to change the law today, what does that mean?,' asked Kim Leadbeater, the MP who introduced the bill last year. 'It means we will have many more years of heartbreaking stories from terminally ill people and their families, of pain and trauma, suicide attempts, PTSD, lonely trips to (clinics in) Switzerland, police investigations.' The option, she said, is 'not a choice between living and dying: it is a choice for terminally ill people about how they die.' But opponents have criticized the bill on religious and ethical grounds, and raised issues with a legislative process they accuse of being opaque. Former British Prime Minister Gordon Brown argued that fixing Britain's strained end-of-live care system should be prioritized, writing in a rare intervention in The Guardian that the bill 'would privilege the legal right to assisted dying without guaranteeing anything approaching an equivalent right to high-quality palliative care for those close to death.' Seriously ill people 'need the health and social care system fixing first,' Labour MP Vicky Foxcroft said in Parliament Friday. 'They want us as parliamentarians to assist them to live, not to die.' Friday's debate was concluded with a free vote, meaning that MPs were allowed to decide for or against the bill according to their conscience, and free from any party-line whipping. The proposed bill is broadly in line with the Oregon model, and does not go as far as Switzerland, the Netherlands and Canada, which allow assisted death in cases of suffering, not just for terminally ill people. It differs from euthanasia, the process in which another person deliberately ends someone's life to relieve suffering. It is currently a crime to help somebody die in England and Wales, punishable by up to 14 years in prison. Performing euthanasia on a person, meanwhile, is considered murder or manslaughter.